Nasdaq
$525.48▲ 0.30%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $133.37BShares out 2.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 2d agoAfter-hours26.10.23 05:104Ownership#●●●
VERTEX PHARMACEUTICALS INC / MA
Daniel J. Brennan, an executive at Vertex Pharmaceuticals, filed a Form 4 on October 22, 2026, reporting a change in beneficial ownership of securities as of October 20, 2026. This filing serves as an official record of the insider's equity transaction.…more
$525.48+0.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 2d agoAfter-hours26.10.23 05:063Ownership
VERTEX PHARMACEUTICALS INC / MA
Vertex Pharmaceuticals has granted a power of attorney to designated representatives, authorizing them to file SEC reports (Forms 3, 4, and 5) on behalf of Daniel Brennan. This action is an administrative procedure to ensure compliance with Section 16 of the Securities Exchange Act of 1934 in his capacity as an officer and director.…more
$525.48+0.30%vs prev closeView filingShare - 4d agoAfter-hours26.10.21 05:098-KKey event
VERTEX PHARMACEUTICALS INC / MA
Vertex Pharmaceuticals appointed Daniel Brennan as a new member of its Board of Directors, effective October 20, 2026. Following this appointment, the Board size increased from ten to eleven members, and Mr. Brennan has joined the Audit and Finance Committee.…more
$525.48+0.30%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.24 02:43Bullish#●●●#●●●#●●●
Vertex Publishes Phase 3 RAINIER Results for IgAN Drug Povetacicept
Vertex's povetacicept demonstrated a 49.8% reduction in proteinuria compared to placebo in Phase 3 trials, with results published in the NEJM. The company is awaiting an FDA decision on accelerated approval scheduled for November 30.…more
$525.48+0.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoRegular26.10.23 01:14
●●●●●●●● ●●●●● ●●●●●●
Vertex Pharmaceuticals' drug candidate, atumelnant, has received Orphan Drug Designation from the FDA for the treatment of endogenous Cushing’s syndrome. This status provides the company with development incentives and potential market exclusivity as it advances clinical trials.…more
$525.48+0.30%vs prev closeShareBenzinga - 3d agoPre-market26.10.22 17:12
●●●●●●●● ●●●●● ●●●●●●
Virtune has aligned the rebalancing schedules of its crypto index ETPs to a quarterly basis to streamline management. This adjustment does not affect investment objectives or fee structures, and no action is required from investors.…more
$525.48+0.30%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report